{"nctId":"NCT01241760","briefTitle":"VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection","startDateStruct":{"date":"2010-12"},"conditions":["Genotype 1 Chronic Hepatitis C","Treatment Naive"],"count":744,"armGroups":[{"label":"001 T(q8h) / PR","type":"EXPERIMENTAL","interventionNames":["Drug: Ribavirin","Drug: Pegylated interferon alfa-2a","Drug: Telaprevir"]},{"label":"002 T(b.i.d.) / PR","type":"EXPERIMENTAL","interventionNames":["Drug: Ribavirin","Drug: Telaprevir","Drug: Pegylated interferon alfa-2a"]}],"interventions":[{"name":"Ribavirin","otherNames":[]},{"name":"Telaprevir","otherNames":[]},{"name":"Pegylated interferon alfa-2a","otherNames":[]},{"name":"Telaprevir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has chronic HCV infection genotype 1 with HCV RNA level \\> 1,000 IU/mL\n* Patients should not have had any previous treatment for hepatitis C\n* Patient must have documentation of a liver biopsy within 2 years before the screening visit or the patient must agree to have a biopsy performed within the screening period\n* Patients with cirrhosis should have serum alpha-fetoprotein (AFP) \\<= 50 ng/mL. If AFP \\> 50 ng/mL, absence of a mass must be demonstrated by ultrasound within the screening period\n* A female patient of childbearing potential and a nonvasectomized male patient who has a female partner of childbearing potential must agree to the use of 2 effective methods of birth control from screening until 6 months (female patient) or 7 months (male patient) after the last dose of RBV.\n\nExclusion Criteria:\n\n* Patient is infected or co-infected with HCV of another genotype than genotype 1 and/or patient is infected with more than one genotype subtype\n* Patient has a pre-existing psychiatric condition\n* Patient has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis C\n* Patient has human immunodeficiency virus (HIV) or hepatitis B virus (HBV) co-infection\n* Patient has active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)","description":"The table below shows the percentage of participants achieving Sustained Virologic Response 12 weeks after last planned dose of study medication (SVR12 planned). SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"74.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)","description":"The table below shows the percentage of participants achieving SVR 24 weeks after the last planned dose of study medication. SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL). The response for T12(b.i.d)/PR group is higher than that after 12 weeks because HCV RNA data for two participants were missing for SVR assessment at that time. Consequently, by definition of SVR12, they were counted as not having achieved SVR12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"74.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)","description":"The table below shows the percentage of participants achieving SVR 72 weeks after the start of study medication (SVR72 planned). SVR was defined as having plasma Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 IU/mL, target not detected, at end of treatment and up to 72 weeks after start of study medication (i.e., no confirmed detectable HCV RNA in between).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":null},{"groupId":"OG001","value":"70.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.","description":"The table below shows the percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels, which means less than 25 IU/ml, target not detected, at different time points during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","spread":null},{"groupId":"OG001","value":"69.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":null},{"groupId":"OG001","value":"66.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs","description":"The table below shows the percentage of participants who met a stopping rule, defined as having a hepatitis C virus (HCV) ribonucleic acid (RNA) value at Week 4 \\>1000 IU/mL and at Weeks 12, 24, 32 and 40 ≥25 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Relapsed During Follow-up Period","description":"The table below shows the percentage of participants who relapsed (ie, those having confirmed detectable hepatitis C virus \\[HCV\\] ribonucleic acid \\[RNA\\] during the 12-week follow-up period after previous HCV RNA \\<25 IU/mL, target not detected, at end of treatment).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)","description":"The table below shows the effect of interleukin 28B (IL28B) gene's subtype (CC, CT or TT genotype) on the primary outcome measure: SVR12 planned.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":null},{"groupId":"OG001","value":"67.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.9","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":371},"commonTop":["Fatigue","Pruritus","Anaemia","Nausea","Rash"]}}}